You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Martin Tammemagi

Senior Scientist, High Risk Lung Scientific Lead, Prevention and Cancer Control, Clinical Institutes and Quality Programs, Ontario Health

Senior Scientist
martin.tammemagi@ontariohealth.ca

Research Interests

  • Lung cancer predictors
  • Predictive risk modelling
  • Cancer epidemiology

Current Appointments

  • Senior Scientist, High Risk Lung Scientific Lead, Prevention and Cancer Control, Clinical Institutes and Quality Programs, Ontario Health
  • Professor, Faculty of Applied Heath Sciences, Department of Health Sciences, Brock University

Selected Past Appointments

  • Associate Professor, Faculty of Applied Heath Sciences, Department of Community Health Sciences, Brock University
  • Senior Epidemiologist, Josephine Ford Cancer Center, Henry Ford Health System

Education and Credentials

  • HBSc, Zoology, University of Toronto
  • DVM, Veterinary Medicine, University of Guelph
  • MSc, Epidemiology, University of Toronto
  • PhD, Epidemiology, University of Toronto
  • MSc, Epidemiology, University of Toronto
  • DVM, Veterinary Medicine, University of Guelph
  • HBSc, Zoology, University of Toronto

Achievements

  • Developed a risk prediction model that calculates a person’s risk of developing lung cancer
  • Led the application of risk criteria within the High Risk Lung Cancer Screening Pilot to support appropriate lung cancer screening through individual risk assessment
  • Led development and implementation of an evaluation of the High Risk Lung Cancer Screening Pilot
  • Provided epidemiological expertise and lead ancillary studies for the Pan-Canadian Early Detection of Lung Cancer Study, U.S. National Cancer Institute’s National Lung Screening Trial, U.S. National Cancer Institute’s Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

Skills and Experience

  • Epidemiology and evaluation to provide scientific support for High Risk Lung Cancer Screening Pilot program implementation
  • Risk modeling expertise to support High Risk Lung Cancer Screening Pilot objectives
  • Mentoring staff to create evidence-based products of strong methodological quality for High Risk Lung Cancer Screening Pilot

 

Selected Publications

Darling GE, Tammemägi MC, Schmidt H, Buchanan DN, Leung Y, McGarry C, Rabeneck L. Organized Lung Cancer Screening Pilot: Informing a Province-Wide Program in Ontario, Canada. Ann Thorac Surg. 2021 Jun;111(6):1805-1811. doi: 10.1016/j.athoracsur.2020.07.051. Epub 2020 Oct 8. PMID: 33039364.

Henderson LM, Durham DD, Tammemägi MC, Benefield T, Marsh MW, Rivera MP. Lung Cancer Screening With Low Dose Computed Tomography in Patients With and Without Prior History of Cancer in the National Lung Screening Trial. J Thorac Oncol. 2021 Jun;16(6):980-989. doi: 10.1016/j.jtho.2021.02.003. Epub 2021 Feb 10. PMID: 33581343.

Tammemägi MC, Darling GE, Schmidt H, Llovet D, Buchanan DN, Leung Y, Miller B, Rabeneck L. Selection of individuals for lung cancer screening based on risk prediction model performance and economic factors - The Ontario experience. Lung Cancer. 2021 Jun;156:31-40. doi: 10.1016/j.lungcan.2021.04.005. Epub 2021 Apr 20. PMID: 33887677.

Walker MJ, Meggetto O, Gao J, Espino-Hernández G, Jembere N, Bravo CA, Rey M, Aslam U, Sheppard AJ, Lofters AK, Tammemägi MC, Tinmouth J, Kupets R, Chiarelli AM, Rabeneck L. Measuring the impact of the COVID-19 pandemic on organized cancer screening and diagnostic follow-up care in Ontario, Canada: A provincial, population-based study. Prev Med. 2021 Oct;151:106586. doi: 10.1016/j.ypmed.2021.106586. PMID: 34217413.

For a full list of Martin Tammemägi's journal articles, visit PubMed.